Mounjaro 10 mg Injection Pen

Description

Mounjaro 10 mg injection pen is a once-weekly injectable medication containing tirzepatide, a dual-action GLP-1 and GIP receptor agonist. It’s designed to improve insulin sensitivity, lower blood sugar, and promote sustained weight loss in adults with type 2 diabetes or obesity.

As the fourth step in the Mounjaro dosing plan (after 2.5 mg, 5 mg, and 7.5 mg), this dose is suited for patients who have tolerated earlier stages and require stronger metabolic control.

Key Features:

• Dual GLP-1 + GIP therapy for enhanced glucose management

• Contains 10 mg tirzepatide per pen

• Once-weekly self-injection for convenience

• Shown to reduce A1C and body weight effectively (FDA Clinical Overview)

• Suitable for long-term treatment progression

Usage Instructions:

• Inject once weekly, on the same day each week

• Administer in the abdomen, thigh, or upper arm

• Rotate injection sites each time

• Begin only after completing 7.5 mg treatment for at least 4 weeks

• Always use as directed by your healthcare provider

Mounjaro 10 mg Injection Pen Side Effects

Temporary side effects may include nausea, stomach discomfort, or fatigue, which generally subside over time. For full safety details, consult the FDA-approved Mounjaro Medication Guide.

Storage Instructions:

• Refrigerate between 36°F–46°F (2°C–8°C)

• Keep in original packaging to protect from light

• Do not freeze or expose to heat